PHOENIX - Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a company engaged in biotech innovation, announced today that it received FDA authorization for an expanded access therapy aimed at preventing Type 1 Diabetes Mellitus (T1D) in individuals at high risk.
The therapy involves CELZ-201, a cell-based program designed to manage abnormal glucose tolerance and potentially preclude the onset of T1D.
The company's CEO, Tim Warbington, expressed optimism about the development, stating that the FDA clearance for CELZ-201 represents a significant step in the company's efforts to introduce new preventive treatments in areas where options are currently limited.
The therapy is part of Creative Medical Technology's broader commitment to personalized medicine and preventing diseases before they manifest.
CELZ-201 is designed to act on a cellular level, targeting abnormal glucose tolerance, which is a precursor to T1D. The company's approach reflects a focus on preemptive care, using advanced science to address health risks before they evolve into full-blown diseases.
The news follows Creative Medical Technology Holdings' broader dedication to developing and deploying FDA-registered biological therapeutics across various medical fields, including immunotherapy, endocrinology, urology, gynecology, and orthopedics.
This announcement is based on a press release statement and comes with the usual caveats of forward-looking statements, which involve inherent risks and uncertainties. The actual outcomes could differ from those projected. Creative Medical Technology Holdings is listed on NASDAQ under the ticker symbol CELZ.
The FDA's authorization of CELZ-201 for expanded access marks a potentially historic moment in the management of T1D, offering new hope for individuals at high risk of developing this chronic condition.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.